[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601647":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":56,"collaborators":20,"id":58,"slug":20,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":20,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Southern College of Optometry","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Qlosi","EXPERIMENTAL","Subjects will be treated with Qlosi™ BID OD\u002FOS, and subjects will only be allowed to use reading glasses for urgent work",[13],"Drug: pilocarpine HCL ophthalmic solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","pilocarpine HCL ophthalmic solution","Qlosi will be given to participants and quality of life will be determined.",[9],null,[22,41],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Complete Eye Care of Medina","RECRUITING","Medina","Minnesota","55340","United States",{"type":30,"coordinates":31},"Point",[32,33],-93.58246,45.03524,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Gina Wesley, OD","CONTACT","763-478-3505","leahlang@cecofmedina.com",{"facility":42,"status":24,"city":43,"state":44,"zip":45,"country":28,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"The Southern College of Optometry","Memphis","Tennessee","38104",{"type":30,"coordinates":47},[48,49],-90.04898,35.14953,{"lat":49,"lon":48},[52],{"name":53,"role":38,"phone":54,"phoneExt":20,"email":55},"Chris Lievens, OD","9014815699","clievens@sco.edu",{"type":57,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100601647",false,"NCT07113210","Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Inclusion Criteria:\n\n* Subjects who are 45-64 years old (inclusive) at the time of screening.\n* Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.\n* Be able and willing to follow all instructions and attend study visits.\n* Have text messaging capabilities on their phone.\n* Self-reported complaints of near vision blur when fully corrected at distance.\n* Study confirmed near add that is between +0.75 D to +2.00 D OD\u002FOS (inclusive).\n* Spherical distance prescription between +1.00 D to -4.00 D OD\u002FOS (inclusive).\n* Cylinder power less than or equal to -1.00 D OD\u002FOS.\n* Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20\u002F20 Snellen equivalent) or better OD\u002FOS.\n\nExclusion Criteria:\n\n* Known hypersensitivity to any ingredient in the study drops.\n* Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).\n* Any use of prescription eye drops 1 week before screening or during the study.\n* Any past use of the study drops.\n* Any contact lens use for the duration of the study.\n* Artificial tears or lubricant eye drops use on the day of or during any study visits.\n* Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could confound study results.\n* Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.\n* A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.\n* Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).","ALL","45 Years","64 Years",{"count":68,"type":69},36,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments\n\n* Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable).\n* Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.",[75,76,77],"Presbyopia","Glasses","Dry Eye","2025-08-07",{"date":80,"type":81},"2025-08-12","ACTUAL",{"date":83,"type":81},"2025-07-18",{"date":85,"type":69},"2025-11-15",{"name":5,"class":6},2]